Biogen

At a glance

Biogen reported 2025 revenue of $9.89B, up 2.2% from $9.68B in 2024. Over 4 years since 2021 ($10.98B), that is a decline of about 2.6% a year. Revenue peaked in 2021 at $10.98B.

In the last 12 months 3 insiders reported 1 open-market purchase ($585) and 3 sales ($905K). All of the sales were made under pre-arranged 10b5-1 trading plans. The largest was a sale of $532K by Head of Development Priya Singhal on Feb 10, 2026. Net, insiders were sellers of $905K.

Biogen filed 13 current reports (Form 8-K) in the last 12 months, most often for results of operations (7), material agreement (2), officer or director change (2) and shareholder vote results (1). The latest officer or director change was reported on Mar 11, 2026. It reported a material agreement or a completed acquisition or disposal 2 times.

2 of the 20 investors tracked here held Biogen at the last quarter end, worth $104.5M combined. It is the largest weight for National Pension Service (Korea) (0.1% of its portfolio), followed by Renaissance Technologies (0%). Added: National Pension Service (Korea). Reduced: Renaissance Technologies.

Annual results

Fiscal year ends Dec 31 · incorporated in DE

Tracked investors holding (13F)

Weight is the share of each investor's portfolio, as of the quarter end.